Cystic Fibrosis Trial, Recruiting NCT06654752 Sponsor: University of Washington, the Collaborative Health Studies Coordinating Center Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT06654752
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children and teenagers aged 6 to under 19 years old (for the main group and the non-HEMT group), or children aged 3 to under 6 years old (for the preschool group)
  • You have been diagnosed with cystic fibrosis (CF), confirmed by a high salt level in a sweat test or by having two CF-causing gene changes
  • You (or your parent/guardian) are willing and able to give written permission to participate, and you are able to follow the study requirements
  • For the main group and preschool group: you have been taking a highly effective CF modulator therapy (a specific type of CF medication) for at least 3 months before joining
  • For the non-HEMT group: you are either not eligible for highly effective modulator therapy based on your gene type, or you have not been taking it for at least 3 months and have no plans to start it in the next year, and you have also not been taking certain other CF medications (tezacaftor-ivacaftor or lumacaftor-ivacaftor) for at least 3 months
  • For the main group and non-HEMT group: you are able to do a breathing test (spirometry) properly and consistently
  • For the main group and non-HEMT group: your lung function score (ppFEV1) is at least 50% of what would be expected for someone your age and size
  • You are able to receive text messages and access the internet

Who may not be able to join:

  • You have a condition that the study doctor believes could put your safety at risk or affect the quality of the study results
  • You are currently taking, or have taken in the past 14 days, a short course of antibiotics by mouth or through a drip (IV) — though you may be able to re-apply at least 21 days after finishing antibiotics if you are back to your usual health
  • You are currently taking, or have taken in the past 14 days, steroid tablets or injections — though you may be able to re-apply at least 21 days after finishing steroids if you are back to your usual health
  • You have previously had an organ transplant (such as a lung, liver, or kidney transplant)
  • A specific type of bacterial infection called Mycobacterium abscessus was found in a test sample of yours in the past 12 months
  • You are currently taking antibiotics to treat a type of bacterial infection called non-tuberculous mycobacteria (NTM)
  • You have needed three or more hospital antibiotic drip (IV) treatments for CF flare-ups in the past 12 months
  • You are currently taking long-term antibiotic tablets or capsules, other than a medication called azithromycin
  • You have been treated with steroid tablets or injections for a lung condition called allergic bronchopulmonary aspergillosis (ABPA) in the past 12 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: D. B. Sanders, MD, MS, Indiana University

Phone: 206-897-1922

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
30 December 2027

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

One-year change in pulmonary function by spirometry-measured ppFEV1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov